Skip to main content
. Author manuscript; available in PMC: 2019 Dec 5.
Published in final edited form as: N Engl J Med. 2019 Dec 5;381(23):2209–2218. doi: 10.1056/NEJMoa1905047

Table 1.

Baseline characteristics of randomised participants

Characteristics TCV (N=10,005) Men A (N=10 014) Total (N= 20019)
Gender
Male N (%) 5106 (51.0%) 5158 (51.5%) 10264 (51.3%)
Age at enrolment (years)
Mean (SD) 7.9 (4.1) 7.8 (4.0) 7.9 (4.1)
Median [Range] 7.7 [0.8 – 16.1] 7.7 [0.7 – 16.1] 7.7 [0.7 – 16.1] *
< 5 years N (%) 2907 (29.1%) 2905 (29.0%)
≥ 5 years N (%) 7098 (70.9%) 7109 (71.0%)
Self-reported medical history of Typhoid fever**
N (%) 345 (3.5%) 395 (4.0%) 740 (3.7%)
*

6 participants are outside the age range for eligibility (9 months to 15 years + 364 days)

**

Self-reported history of typhoid infection prior to the beginning of the study, reported at baseline intake

TCV = Typhoid Conjugate Vaccine. Men A = Group A meningococcal vaccine (control)